Prospective safety study of immunotherapy administered in a cluster schedule

Journal of Investigational Allergology and Clinical Immunology

Volumn 14, Issue 4, 2004, Pages 312-319

  Serrano, P ^a   Algorta, J ^b,c   Martinez A ^b   Gonzalez Quevedo T ^a   Velazquez E ^a   Diaz M ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b R and D Department   (Spain)

^c HOSPITAL TXAGORRITXU   (Spain)

Author keywords

Adverse reaction; Allergy; Cluster immunotherapy; Desensitisation, immunologic; Desensitisation, immunologic adverse effects; Drug administration schedule; General; Immunotherapy; MeSH; Respiratory hypersensitivity asthma, rhinitis

Indexed keywords

ADRENALIN; ALLERGEN; HOUSE DUST ALLERGEN; POLLEN EXTRACT;

ADULT; ALLERGIC DISEASE; ALLERGIC RHINITIS; ALLERGIC URTICARIA; ALTERNARIA; ALTERNARIA ALTERNATA; ANAPHYLAXIS; ARTICLE; ASTHMA; BRONCHOSPASM; CHEMICAL COMPOSITION; CLUSTER ANALYSIS; CLUSTER IMMUNOTHERAPY; CONTROLLED STUDY; DERMATOPHAGOIDES PTERONYSSINUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG ADMINISTRATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; FEMALE; HUMAN; IMMUNOTHERAPY; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; OLIVE TREE; OPEN STUDY; OUTPATIENT; PATIENT COMPLIANCE; PERENNIAL RYEGRASS; POLLEN ALLERGY; POLLINATION; PRICK TEST; PROSPECTIVE STUDY; RHINOCONJUNCTIVITIS; RISK ASSESSMENT; SAFETY; SEASONAL VARIATION; SHORT COURSE THERAPY; SIDE EFFECT;

ADOLESCENT; ADULT; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; HYPERSENSITIVITY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 15044341738     PISSN: 10189068     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Bousquet J, Lockey RF, Malling H-J, editors. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53 Suppl, 44:1-42.
2. Bousquet J., Van Cauwenberge P., Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 Suppl):S147-334.
3. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomised controlled trials. Am J Respir Crit Care Med 1995;151(4):969-74.
4. Malling HJ, Weeke B, eds. EAAC1 Position Paper on Immunotherapy. Allergy 1993;48(Suppl. 14):1-81.
5. Dreborg S, Frew A. Allergen standardization and skin tests. EAACI Position Paper. Allergy 1993;48(Suppl. 14):49-82.
6. Martínez A, Martínez J, Llamazares A, Palacios R. Comparison of in-house reference extracts of Dermatophagoides pteronyssinus and Phleum pratense with the WHO International Standards. Allergol Immunopathol 1992;20:106-12.
7. Sharkey P, Portnoy J. Rush immunotherapy: experience with a one-day schedule. Ann Allergy Asthma immunol 1996;76:175-80.
8. Tabar AI, García BE, Rodríguez A, Olaguibel JM, Muro MD, Quirce S. A prospective safety-monitoring study of immunotherapy with biologically standardized extracts. Allergy 1993;48:450-3.
9. Akmanlar N, Altintas DU, Guneser KS, Yilmaz M, Bingol G. Comparison of conventional and rush immunotherapy with der P1 in childhood respiratory allergy. Allergol Immunopathol 2000;28:213-8.
10. Gastaminza G, Algorta J, Audicana M, Etxenagusia M, Fernández E, Muñoz D. Systemic reactions to immunotherapy: influence of composition and manufacturer. Clin Exp Allergy 2003;33:470-4.
11. Portnoy J, King K, Kanarek H, Horner S. Incidence of systemic reactions during rush immunotherapy. Ann Allergy 1992;68:493-8.
12. Winther L, Malling HJ, Mosbech H. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects. Allergy 2000;55:827-35.
13. Luigi A, Senna G, Mezzelani P, Pappalardo G. Safety of specific immunotherapy: A retrospective study. J Invest Allergol Clin Immunol 1994;4:250-4.